ADC Therapeutics SA (ADCT)
3.73
-0.38
(-9.25%)
USD |
NYSE |
May 21, 16:00
3.74
+0.01
(+0.27%)
Pre-Market: 20:00
ADC Therapeutics Cash from Operations (TTM): -147.39M for March 31, 2024
Cash from Operations (TTM) Chart
Historical Cash from Operations (TTM) Data
| Date | Value |
|---|---|
| March 31, 2024 | -147.39M |
| December 31, 2023 | -118.69M |
| September 30, 2023 | -139.23M |
| June 30, 2023 | -103.02M |
| March 31, 2023 | -119.82M |
| December 31, 2022 | -138.31M |
| September 30, 2022 | -146.33M |
| Date | Value |
|---|---|
| June 30, 2022 | -207.11M |
| March 31, 2022 | -212.11M |
| December 31, 2021 | -233.38M |
| September 30, 2021 | -223.44M |
| June 30, 2021 | -209.14M |
| March 31, 2021 | -191.78M |
| December 31, 2020 | -168.73M |
Cash From Operations Definition
Cash flow from operations is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall operating activities of the company. A few examples of operating activities include change in receivables, change in inventories, and changes in current assets.
Cash from Operations (TTM) Range, Past 5 Years
-233.38M
Minimum
Dec 2021
-103.02M
Maximum
Jun 2023
-168.46M
Average
-158.06M
Median
Cash from Operations (TTM) Benchmarks
| Roche Holding AG | 18.04B |
| Novartis AG | 13.77B |
| AC Immune SA | -47.96M |
| CRISPR Therapeutics AG | -159.42M |
| Addex Therapeutics Ltd | -8.901M |